Summit Therapeutics (SMMT) is moving sharply lower after releasing quarterly results showing a much wider loss and a major step-up in operating spend tied to its late-stage oncology push around ivonescimab (SMT112). The company reported a Q1 2026 GAAP net loss of $189.4 million (vs. $62.9 million a year ago) and disclosed materially higher R&D and G&A expense levels, reflecting the costs of initiating and expanding multiple global studies. (smmttx.com)

R&D expense jumped to $132.6 million in Q1 2026 from $51.2 million in Q1 2025, while G&A expense rose to $62.6 million from $15.6 million year over year, with the company attributing a meaningful portion of the increase to stock-based compensation tied to earlier performance-based award modifications and broader infrastructure buildout. Investors often treat these step-changes as signals that total program costs could stay elevated for multiple quarters as registrational and combination trials run in parallel. (smmttx.com)

The selloff is landing ahead of several key clinical and regulatory milestones that still sit in the future, including an overall survival presentation from HARMONi-6 slated for the ASCO 2026 Plenary Session and an FDA PDUFA date of Nov. 14, 2026 for an ivonescimab BLA in EGFR-mutated non-squamous NSCLC. Summit also disclosed it ended March 31, 2026 with $598.7 million in cash and short-term investments, a figure investors are weighing against the higher quarterly burn rate. (smmttx.com)

Near-term trading may hinge on whether investors view the expense ramp as a temporary investment phase or a sign that funding needs could re-emerge before the FDA decision window. Attention is likely to stay on the cadence of Phase III enrollment updates, the quality of any new survival readouts around ASCO, and any signals about capital-market activity given the company’s disclosed at-the-market program language in its filings. (stocktitan.net)